Elucida Research LLC, Beverly, MA, USA.
University of Massachusetts School of Medicine, Worcester, MA, USA.
Curr Opin Lipidol. 2020 Apr;31(2):94-100. doi: 10.1097/MOL.0000000000000665.
The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight.
Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of ω-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed ω-3 fatty acids.
In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription ω-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events.
本综述旨在评估根据其成分和监管监督水平的综合分析,食用鱼油补充剂是否适合患有高甘油三酯和心血管风险的患者。
美国约有 1900 万人服用鱼油补充剂,其中许多人是为了治疗或预防心脏病。与处方药不同,鱼油补充剂被食品和药物管理局 (FDA) 归类为食品,不需要进行生产监督或临床测试。对广泛使用的膳食鱼油补充剂的分析表明,它们的 ω-3 含量可能低于广告宣传的水平,而且还含有大量的饱和脂肪和氧化油,实际上可能导致血脂异常。鱼油补充剂和其他低剂量混合 ω-3 脂肪酸的临床结果试验未能显示出一致的心血管益处。
鉴于监管监督有限且存在质量问题,膳食鱼油补充剂不适合替代 FDA 批准的处方 ω-3 脂肪酸,用于治疗高甘油三酯或预防心血管事件。